Cite
HARVARD Citation
Shimada, N. et al. (2014). A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Hepatology research. 44 (14), pp. E386-E396. [Online].